Compare MCB & LENZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MCB | LENZ |
|---|---|---|
| Founded | 1999 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 833.3M | 852.0M |
| IPO Year | 2017 | 2021 |
| Metric | MCB | LENZ |
|---|---|---|
| Price | $81.97 | $17.21 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $90.00 | $56.25 |
| AVG Volume (30 Days) | 81.3K | ★ 1.2M |
| Earning Date | 01-22-2026 | 11-05-2025 |
| Dividend Yield | ★ 0.74% | N/A |
| EPS Growth | ★ 8.50 | N/A |
| EPS | ★ 5.80 | N/A |
| Revenue | ★ $261,456,000.00 | $17,500,000.00 |
| Revenue This Year | $15.57 | N/A |
| Revenue Next Year | $13.99 | $204.72 |
| P/E Ratio | $13.94 | ★ N/A |
| Revenue Growth | ★ 1.27 | N/A |
| 52 Week Low | $47.08 | $15.70 |
| 52 Week High | $82.45 | $50.40 |
| Indicator | MCB | LENZ |
|---|---|---|
| Relative Strength Index (RSI) | 73.65 | 25.38 |
| Support Level | $79.08 | $16.30 |
| Resistance Level | $82.45 | $29.02 |
| Average True Range (ATR) | 2.73 | 2.26 |
| MACD | 0.35 | -1.03 |
| Stochastic Oscillator | 95.07 | 9.04 |
Metropolitan Bank Holding Corp is a bank holding company. It provides a broad range of business, commercial, and retail banking products and services to small businesses, middle-market enterprises, public entities, and individuals in the New York metropolitan area. The services provided by the company include deposits, trade finance, cash management solutions, savings, electronic banking, cards, and others. The company also provides various lending products such as acquisition loans, construction loans, and lines of credit, for retail, office, hospitality, multifamily, mixed-use, warehouse and distribution, and specialty-use properties. The bank derives its revenue in the form of interest income on loans.
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.